|
1
|
Antithrombotic Trialists’ (ATT)
Collaboration. Aspirin in the primary and secondary prevention of
vascular disease: collaborative meta-analysis of individual
participant data from randomised trials. Lancet. 373:1849–1860.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fazekas F, Fazekas G, Schmidt R, Kapeller
P and Offenbacher H: Magnetic resonance imaging correlates of
transient cerebral ischemic attacks. Stroke. 27:607–611. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Easton JD, Saver JL, Albers GW, et al:
Definition and evaluation of transient ischemic attack: a
scientific statement for healthcare professionals from the American
Heart Association/American Stroke Association Stroke Council;
Council on Cardiovascular Surgery and Anesthesia; Council on
Cardiovascular Radiology and Intervention; Council on
Cardiovascular Nursing; and the Interdisciplinary Council on
Peripheral Vascular Disease. The American Academy of Neurology
affirms the value of this statement as an educational tool for
neurologists. Stroke. 40:2276–2293. 2009.
|
|
4
|
Coull AJ, Lovett JK and Rothwell PM;
Oxford Vascular Study. Population based study of early risk of
stroke after transient ischaemic attack or minor stroke:
implications for public education and organisation of services.
BMJ. 328:3262004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnston SC, Rothwell PM, Nguyen-Huynh MN,
et al: Validation and refinement of scores to predict very early
stroke risk after transient ischaemic attack. Lancet. 369:283–292.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luengo-Fernandez R, Gray AM and Rothwell
PM: Effect of urgent treatment for transient ischaemic attack and
minor stroke on disability and hospital costs (EXPRESS study): a
prospective population-based sequential comparison. Lancet Neurol.
8:235–243. 2009. View Article : Google Scholar
|
|
7
|
Wang Y, Wang Y, Zhao X, et al: Clopidogrel
with aspirin in acute minor stroke or transient ischemic attack. N
Engl J Med. 369:11–19. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Diener HC, Bogousslavsky J, Brass LM, et
al: Aspirin and clopidogrel compared with clopidogrel alone after
recent ischaemic stroke or transient ischaemic attack in high-risk
patients (MATCH): randomised, double-blind, placebo-controlled
trial. Lancet. 364:331–337. 2004. View Article : Google Scholar
|
|
9
|
Eikelboom JW, Hirsh J, Spencer FA, Baglin
TP and Weitz JI: Antiplatelet drugs: Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines. Chest.
141(2 Suppl): e89S–e119S. 2012. View Article : Google Scholar
|
|
10
|
CAST (Chinese Acute Stroke Trial)
Collaborative Group. CAST: randomised placebo-controlled trial of
early aspirin use in 20,000 patients with acute ischaemic stroke.
Lancet. 349:1641–1649. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
International Stroke Trial Collaborative
Group. The International Stroke Trial (IST): a randomised trial of
aspirin, subcutaneous heparin, both, or neither among 19435
patients with acute ischaemic stroke. Lancet. 349:1569–1581. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kennedy J, Hill MD, Ryckborst KJ, Eliasziw
M, Demchuk AM and Buchan AM; FASTER Investigators. Fast assessment
of stroke and transient ischaemic attack to prevent early
recurrence (FASTER): a randomised controlled pilot trial. Lancet
Neurol. 6:961–969. 2007. View Article : Google Scholar
|
|
13
|
Shinohara Y, Katayama Y, Uchiyama S, et
al; CSPS 2 group. Cilostazol for prevention of secondary stroke
(CSPS 2): an aspirin-controlled, double-blind, randomised
non-inferiority trial. Lancet Neurol. 9:959–968. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shinohara Y, Gotoh F, Tohgi H, et al:
Antiplatelet cilostazol is beneficial in diabetic and/or
hypertensive ischemic stroke patients. Subgroup analysis of the
cilostazol stroke prevention study. Cerebrovasc Dis. 26:63–70.
2008. View Article : Google Scholar
|
|
15
|
Huang Y, Cheng Y, Wu J, et al; Cilostazol
versus aspirin for secondary ischaemic stroke prevention (CASISP)
cooperation investigators. Cilostazol as an alternative to aspirin
after ischaemic stroke: a randomised, double-blind, pilot study.
Lancet Neurol. 7:494–499. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nishiyama K, Seyama H, Okano H, et al:
Escalation regimen of cilostazol for acute brain infarction. Intern
Med. 50:1559–1563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chi YW, Lavie CJ, Milani RV and White CJ:
Safety and efficacy of cilostazol in the management of intermittent
claudication. Vasc Health Risk Manag. 4:1197–1203. 2008.PubMed/NCBI
|
|
18
|
Otsuki M, Saito H, Xu X, et al: Cilostazol
represses vascular cell adhesion molecule-1 gene transcription via
inhibiting NF-kappaB binding to its recognition sequence.
Atherosclerosis. 158:121–128. 2001. View Article : Google Scholar : PubMed/NCBI
|
